Jul 15, 2026 05:11AM
Jul 6, 2026 06:50AM
Jul 6, 2026 06:50AM
Jun 15, 2026 06:50AM
Jun 15, 2026 06:50AM
May 12, 2026 04:05PM
May 8, 2026 06:01AM Pharvaris prices $115 million share offering at $29.68 per share
May 8, 2026 06:00AM
Apr 20, 2026 06:50AM
Apr 20, 2026 06:50AM
Apr 2, 2026 06:50AM
Mar 20, 2026 06:51AM
Mar 20, 2026 06:50AM
Mar 11, 2026 06:50AM Pharvaris publishes study validating patient outcomes in hereditary angioedema
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 2, 2026 06:55AM
Mar 2, 2026 06:50AM
Jan 12, 2026 06:50AM
Jan 12, 2026 06:50AM
Dec 3, 2025 06:50AM Pharvaris reports positive results from HAE treatment study
Dec 3, 2025 06:50AM
Nov 12, 2025 06:50AM
Nov 10, 2025 06:50AM
Aug 12, 2025 04:05PM
Jul 10, 2025 06:51AM
Jul 10, 2025 06:50AM
Jun 16, 2025 06:50AM Pharvaris (PHVS) Presents Data Highlighting the Potential for Deucrictibant
Jun 16, 2025 06:50AM
Jun 2, 2025 06:52AM
Jun 2, 2025 06:50AM
May 13, 2025 04:05PM
Apr 7, 2025 06:58AM
Apr 1, 2025 06:50AM
Apr 1, 2025 06:50AM Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Mar 3, 2025 06:50AM
Mar 3, 2025 06:50AM
Jan 13, 2025 06:52AM
Jan 13, 2025 06:50AM
Nov 13, 2024 04:10PM
Oct 24, 2024 08:00AM
Sep 5, 2024 06:50AM Pharvaris (PHVS) Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE
Sep 5, 2024 06:50AM
Sep 5, 2024 06:50AM
Sep 5, 2024 06:49AM
Sep 5, 2024 06:48AM
Aug 14, 2024 06:50AM
Aug 1, 2024 08:00AM
Jun 4, 2024 06:50AM Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
May 14, 2024 02:20AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All